176 related articles for article (PubMed ID: 35738074)
1. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
[TBL] [Abstract][Full Text] [Related]
2. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
3. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.
Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y
Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706
[TBL] [Abstract][Full Text] [Related]
4. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
5. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
6. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
7. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.
Kantara C; O'Connell M; Sarkar S; Moya S; Ullrich R; Singh P
Cancer Res; 2014 May; 74(9):2487-98. PubMed ID: 24626093
[TBL] [Abstract][Full Text] [Related]
8. A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy.
Sarkar S; Popov VL; O'Connell MR; Stevenson HL; Lee BS; Obeid RA; Luthra GK; Singh P
Lab Invest; 2017 Oct; 97(10):1245-1261. PubMed ID: 28414327
[TBL] [Abstract][Full Text] [Related]
9. Honokiol Affects Stem Cell Viability by Suppressing Oncogenic YAP1 Function to Inhibit Colon Tumorigenesis.
Subramaniam D; Ponnurangam S; Ramalingam S; Kwatra D; Dandawate P; Weir SJ; Umar S; Jensen RA; Anant S
Cells; 2021 Jun; 10(7):. PubMed ID: 34206989
[TBL] [Abstract][Full Text] [Related]
10. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.
Ito H; Tanaka S; Akiyama Y; Shimada S; Adikrisna R; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Yamaoka S; Tanabe M
PLoS One; 2016; 11(1):e0146564. PubMed ID: 26764906
[TBL] [Abstract][Full Text] [Related]
11. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
12. Exosomes from metastatic colon cancer cells drive the proliferation and migration of primary colon cancer through increased expression of cancer stem cell markers CD133 and DCLK1.
Yasodha K; Lizha Mary L; Surajit P; Satish R
Tissue Cell; 2023 Oct; 84():102163. PubMed ID: 37487255
[TBL] [Abstract][Full Text] [Related]
13. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications.
O'Connell MR; Sarkar S; Luthra GK; Okugawa Y; Toiyama Y; Gajjar AH; Qiu S; Goel A; Singh P
Sci Rep; 2015 Oct; 5():14983. PubMed ID: 26447334
[TBL] [Abstract][Full Text] [Related]
15. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
[TBL] [Abstract][Full Text] [Related]
16. Induction of let-7e gene expression attenuates oncogenic phenotype in HCT-116 colorectal cancer cells through targeting of DCLK1 regulation.
Khodadadi Kohlan A; Saidijam M; Amini R; Samadi P; Najafi R
Life Sci; 2019 Jul; 228():221-227. PubMed ID: 31075231
[TBL] [Abstract][Full Text] [Related]
17. Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line.
Li L; Bellows CF
Chin J Cancer Res; 2013 Apr; 25(2):134-42. PubMed ID: 23592893
[TBL] [Abstract][Full Text] [Related]
18. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1.
Zhou B; Sun C; Hu X; Zhan H; Zou H; Feng Y; Qiu F; Zhang S; Wu L; Zhang B
Cell Physiol Biochem; 2017; 44(5):1867-1881. PubMed ID: 29224010
[TBL] [Abstract][Full Text] [Related]
20. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
Wang J; Wang S; Zhou J; Qian Q
Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]